We recently published a list of Thursday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to ...

H.C. Wainwright lowered the firm’s price target on Alumis (ALMS) to $15 from $19 and keeps a Buy rating on the shares following the Q4 report.

March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and ...

SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...

Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated ...

Alumis Inc., a clinical-stage biopharmaceutical company, announced key developments in its pipeline and a merger with ACELYRIN during its recent financial results release. At the AAD 2025 ...

Automated three-dimensional total-body photography improves the efficiency of positive malignant biopsies and reduces ...

D-Wave Quantum fell for a third straight day on Thursday, losing 18.02 percent to end at $8.69 each as investors sold off ...

Alumis Inc. (NASDAQ:ALMS – Get Free Report) has received a consensus rating of “Buy” from the nine analysts that are presently covering the firm, Marketbeat Ratings reports.Seven investment ...